Panobinostat SR is under clinical development by Midatech Pharma and currently in Phase I for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Recurrent Glioblastoma Multiforme (GBM) have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Panobinostat SR’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Panobinostat SR overview

Panobinostat is under development for the treatment of diffuse intrinsic pontine glioma (DIPG), recurrent medulloblastoma and glioblastoma. The drug candidate is administered through intratumoral convection enhanced delivery in the form of liquid dosage, as a subcutaneously implanted pump and intraventricular route. It is a formulation of panobinostat utilizing NI technology to enhance solubility and allow localized delivery. Panobinostat targets histone deacetylase (HDAC). The drug candidate is developed based on the Midasolve technology platform.

Midatech Pharma overview

Midatech Pharma (Midatech) is a pharmaceutical company that develops and commercializes products in oncology and other therapeutic areas. The company’s products include gelclair, oravig, soltamox and zuplenz. It conducts research and development programs in the areas of oncology, autoimmune diseases, pipeline, Q-octreotide, opsisporin, HCC, glioblastoma and diabetes vaccine. Midatech’s products are used in treatment of diabetes; rare cancers including brain, ovarian, liver and pancreatic cancer and neurological and ophthalmologic conditions, among others. It collaborates with universities, and specialty and major pharmaceutical companies to develop its platform technologies. The company operates through its manufacturing facility in Bilbao, and research facility in Cardiff. Midatech is headquartered in Abingdon, the UK.

For a complete picture of Panobinostat SR’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.